PTPRC and neoplasm: After concurrent with reduced tumor growth, the Ce6-PDT treatment increased the percentage of CD3+ CD4+ tumor-infiltrating T cells and CD45+ , a leukocyte common antigen, indicating an increased immune activation (Fig. 3A,B).